Pediatric exome sequencing narrows a search across roughly 20,000 protein-coding genes to find the single variant behind a child's unexplained symptoms, and choosing the wrong test format at Yaazh Xenomics or any other lab can add months to a diagnosis that a child's care team can't afford to lose.
- Trio exome sequencing (child plus both parents) is the safe pick for undiagnosed pediatric cases in 2026 — Buy.
- Singleton exome works only when parental samples are unavailable; diagnostic yield drops without trio context — Consider.
- Rapid exome for NICU-level cases needs a lab that prioritizes critical turnaround, not a standard queue — Consider.
- Gene panels look cheaper but miss the 25-40% of cases exome sequencing catches in published pediatric cohorts — Skip for undiagnosed disorders.
- Yaazh Xenomics runs NGS-based exome sequencing with ISO 9001:2015 certified processes and 99.9% base accuracy on its platform.
Why this matters
A child with a suspected genetic disorder usually arrives after a string of normal blood panels, normal MRIs, and a pediatrician who has run out of single-gene tests to order. Exome sequencing for pediatric genetic disorders exists precisely for that gap — it reads the coding regions of nearly every gene at once instead of testing one hypothesis at a time.
The Yaazh Xenomics genomics lab in Coimbatore processes exome and whole-genome samples for clinical and academic partners across India, and the format you choose (trio, singleton, rapid, or exome-plus) changes both cost and diagnostic yield. Get the format wrong and you either overpay for speed you don't need or underpay for accuracy the case demands.
Who this is for
This guide is for pediatric neurologists, clinical geneticists, and NICU teams ordering exome sequencing for a child with a suspected Mendelian disorder — developmental delay, seizures, dysmorphic features, or a metabolic presentation that hasn't resolved with targeted panels. It's also for genetic counselors advising families on which format to request before a sample ships to the lab in 2026.
What to look for in exome sequencing for pediatric genetic disorders
Trio capability, not just singleton sequencing
A lab that can only run the child's sample forces you into singleton exome sequencing, which strips out the parental context that resolves ambiguous variants. Trio analysis — sequencing both biological parents alongside the child — lifts diagnostic yield by roughly 10 percentage points over singleton testing in published pediatric cohort data, because inheritance pattern alone can rule out or confirm a candidate variant in hours instead of weeks of follow-up testing.
Coverage depth across the coding exome
Depth of coverage determines whether a low-frequency mosaic variant gets called or missed entirely. For pediatric cases, uniform coverage across the exome — not just average depth — matters more, since a single missed exon in a disease gene is the difference between a diagnosis and another year of testing.
CNV and mitochondrial detection built into the exome workflow
Standard exome pipelines are tuned for single-nucleotide and small indel variants, but a meaningful share of pediatric genetic disorders trace back to copy number variants or mitochondrial DNA changes. A lab running exome-plus-CNV analysis as a standard add-on catches cases that a plain exome report would flag as "no pathogenic variant found."
Bioinformatics pipeline transparency
Ask what variant classification framework the lab applies — ACMG/AMP guidelines are the accepted standard for pediatric variant interpretation in 2026. A lab that can't explain its filtering and classification pipeline is a lab that can't defend a report in front of a family or a referring physician.
Turnaround time matched to clinical urgency
A developmental delay workup and a NICU case with a decompensating infant are not the same clinical timeline. Rapid or urgent exome protocols exist for a reason — a standard queue that takes weeks is the wrong choice when a child is in intensive care and management decisions hinge on the result.
Report clarity for non-geneticist referring physicians
The report has to be usable by the pediatrician who ordered it, not just the geneticist who reads variant call format files. Look for structured reports with a clear primary finding, secondary findings policy, and a variant classification the referring physician can act on without translation.
Top picks for pediatric exome sequencing formats
Trio exome sequencing — the safe pick. One spec that matters: parental samples processed alongside the proband in the same NGS run. Published pediatric cohorts report diagnostic yields of 25-40% with trio exome sequencing, versus lower rates for singleton testing alone. Buy — this is the default format for any undiagnosed pediatric case where both parents are available and consenting.
Singleton exome sequencing — the fallback pick. One spec that matters: single-sample variant calling without inheritance filtering. Useful when parental samples can't be collected — adoption cases, deceased parents, or non-paternity concerns — but expect a longer variant review cycle since candidate variants need orthogonal confirmation. Consider when trio isn't feasible, not as a first choice.
Rapid/urgent exome sequencing — the wildcard pick. One spec that matters: prioritized sample processing for time-critical cases, typically NICU or PICU admissions where a result changes immediate management. Critical care exome programs in published literature report turnaround compressed to under two weeks against a standard multi-week queue. Consider for any child where a diagnosis changes treatment within days, not months.
Exome-plus-CNV/mitochondrial panel — the comprehensive pick. One spec that matters: combined short-variant and copy-number analysis from the same sequencing run instead of a separate test. This format catches structural and mitochondrial causes that a plain exome misses, which matters most in cases with a strong clinical suspicion but a negative standard exome. Buy for cases where an initial exome came back negative and clinical suspicion remains high.
Gene panel testing (for comparison) — the wrong tool here. One spec that matters: panels test 50-300 pre-selected genes versus roughly 20,000 in an exome. Panels are cheaper and faster when the clinical picture points to a specific disorder, but for undiagnosed, phenotypically ambiguous pediatric cases, a panel's fixed gene list is its ceiling. Skip for undiagnosed presentations — order exome sequencing instead.
What to avoid
- Ordering singleton exome sequencing by default when parental samples are collectible — you're trading diagnostic yield for a small logistics saving.
- Choosing a lab without a documented CNV-detection add-on and assuming a negative exome report closes the case — it may only mean the pipeline wasn't built to look at structural variants.
- Treating turnaround time as a fixed number across all labs — a lab's headline turnaround for one service line (like NIPT) doesn't automatically apply to exome sequencing, which runs a different workflow.
If cost is the deciding factor between exome and whole-genome approaches for a pediatric case, the tradeoffs are laid out in Yaazh Xenomics' whole genome sequencing cost breakdown, which covers what drives price differences between the two approaches in 2026.
Discuss a pediatric exome case
Get format and turnaround guidance before the sample ships.
Verdict comparison table
| Format | Best for | Diagnostic yield signal | Verdict |
|---|---|---|---|
| Trio exome sequencing | Undiagnosed cases, parents available | 25-40% per published cohorts | Buy |
| Singleton exome sequencing | Parents unavailable | Lower than trio, needs confirmation | Consider |
| Rapid/urgent exome | NICU/PICU, time-critical | Turnaround under two weeks in critical care programs | Consider |
| Exome-plus-CNV/mitochondrial | Negative standard exome, high suspicion | Catches structural/mito causes missed by plain exome | Buy |
| Gene panel (50-300 genes) | Specific, confirmed clinical suspicion | Fixed gene list ceiling | Skip for undiagnosed cases |
FAQ
What is exome sequencing for pediatric genetic disorders?
It's a next-generation sequencing test that reads the protein-coding regions of nearly all genes in a child's DNA to find variants causing an undiagnosed genetic condition. It's typically ordered after single-gene or panel tests fail to explain a child's symptoms.
Is trio exome sequencing better than singleton for children?
Yes, trio exome sequencing (child plus both parents) improves diagnostic yield by roughly 10 percentage points over singleton testing in published pediatric cohorts. Parental samples let the lab confirm inheritance patterns without extra follow-up testing.
How much does pediatric exome sequencing cost in India?
Cost depends on whether the test is singleton or trio, and whether CNV analysis is bundled in. A detailed cost breakdown comparing exome and whole-genome pricing in India for 2026 is available on Yaazh Xenomics' site.
What is the diagnostic yield of exome sequencing in pediatric cases?
Published pediatric cohort studies report diagnostic yields between 25% and 40% for trio exome sequencing in undiagnosed cases. Yield is lower for singleton testing and higher when combined with CNV analysis.
How fast can exome sequencing results come back for a NICU case?
Rapid or urgent exome protocols in critical care programs report turnaround compressed to under two weeks, against several weeks for a standard queue. Confirm with the lab whether rapid processing is available before the sample ships.
Should I choose exome sequencing or a gene panel for my child?
Choose a gene panel only when the clinical picture points to a specific, well-defined disorder with a known gene list. For undiagnosed or phenotypically ambiguous presentations, exome sequencing covers roughly 20,000 genes instead of a panel's fixed 50-300.
Does exome sequencing detect copy number variants in children?
Standard exome pipelines are built for small variants, not structural changes, so copy number detection depends on whether the lab runs a CNV-specific add-on. Ask explicitly whether CNV and mitochondrial analysis are included before ordering.
What accreditation should a pediatric exome sequencing lab have?
Look for ISO 9001:2015 certification and a documented ACMG/AMP-based variant classification framework. Yaazh Xenomics runs its exome sequencing workflow under ISO 9001:2015 certified processes with 99.9% base accuracy on its NGS platform.
One last thing
The detail most referring physicians miss in 2026: a negative exome report is not the end of the diagnostic road if the pipeline wasn't built to catch copy number or mitochondrial variants — ask the lab explicitly what its exome workflow does and doesn't detect before treating a negative result as final.